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Abstract Diabetes mellitus is a widespread disease prev-
alence and incidence of which increases worldwide. The
introduction of insulin therapy represented a major break-
through in type 1 diabetes; however, frequent hyper- and
hypoglycemia seriously affects the quality of life of these
patients. New therapeutic approaches, such as whole
pancreas transplant or pancreatic islet transplant, stem cell,
gene therapy and islets encapsulation are discussed in this
review. Regarding type 2 diabetes, therapy has been based
on drugs that stimulate insulin secretion (sulphonylureas
and rapid-acting secretagogues), reduce hepatic glucose
production (biguanides), delay digestion and absorption of
intestinal carbohydrate (alpha-glucosidase inhibitors) or
improve insulin action (thiazolidinediones). This review is
also focused on the newer therapeutically approaches such
as incretin-based therapies, bariatric surgery, stem cells and
other emerging therapies that promise to further extend the
options available. Gene-based therapies are among the most
promising emerging alternatives to conventional treatments.
Some of these therapies rely on genetic modification of
non-differentiated cells to express pancreatic endocrine
developmental factors, promoting differentiation of non-
endocrine cells into β-cells, enabling synthesis and
secretion of insulin in a glucose-regulated manner.
Alternative therapies based on gene silencing using
vector systems to deliver interference RNA to cells (i.e.
against VEGF in diabetic retinopathy) are also a
promising therapeutic option for the treatment of several
diabetic complications. In conclusion, treatment of
diabetes faces now a new era that is characterized by a
variety of innovative therapeutic approaches that will
improve quality-life and allow personalized therapy-
planning in the near future.
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Introduction
Diabetes mellitus is increasing globally affecting more than
180 million people worldwide [1]. This is mostly type 2
diabetes and, because of the increase in the aging
population and massive rise in prevalence of obesity, the
incidence is likely to be more than doubled by 2030 [1, 2].
Diabetes is a global problem with devastating human,
social and economic impact. A major concern with the
diabetes epidemic is the anticipated increase in mortality
and morbidity related to the complications of the disease [3,
4]. Insufficient drug therapies, poor patient compliance to
therapy and inadequate management regimes may be
contribute to the increasing incidence of complications
linked to the disease.
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Glycemic control
Glycemic control is fundamental to the management of
diabetes. It is now established that the risk of diabetic
complications is dependent on the degree of glycemic control
in diabetic patients. Clinical trials such as the Diabetes Control
and Complications Trial [5] and the Stockholm Diabetes
Study in type 1 diabetes [6], and the UK Prospective Diabetes
study [7, 8] and Kumamoto study [9] in type 2 diabetes,
have demonstrated that tight glycemic control achieved
with intensive insulin regimes can reduce the risk of
developing or progressing retinopathy, nephropathy and
neuropathy in patients with all types of diabetes. However,
the Third National Health and Nutrition Examination
Survey (NHANES III) showed that only 50% of diabetics
have been able to achieve a glycosylated hemoglobin
(HbA1C) level, as an index of chronic glycemia, less than 7%;
therefore, the only way to ensure the long-term health of
diabetic patients is to maintain constant normoglycaemia [2].
The goal of antidiabetes therapy is to reduce hyperglycemia
to either prevent or minimize the complications associated
with this disease. HbA1C levels are a measure of glycemic
control, and antidiabetes treatment aims to reduce HbA1C to
as close to normal (<6.0%) as possible, without inducing
hypoglycemia. Improved glycemic control is associated with
significant reductions in microvascular complications, such as
retinopathy, nephropathy, and neuropathy [7, 8]. In a meta-
analysis, tight glycemic control has also been shown to
reduce cardiovascular disease [10]. As a result, a clinical trial
is currently investigating whether reducing HbA1C to less
than 6.0% decreases the rate of cardiovascular disease and
death [11, 12], which would be clinically beneficial as
macrovascular disease accounts for approximately 50% of
deaths in individuals with type 2 diabetes.
In type 2 diabetes, despite the clinical benefits of tight
glycemic control and the availability of many distinct
antidiabetic agents, treatments tend to become less effective
over time as insulin resistance increases and pancreatic β-
cell function deteriorates. Patients with type 1 diabetes are
unable to maintain normoglycemia at all times, even with
an intensive insulin therapy.
Insight into the pathophysiology of diabetes and its
complications has led to the development of improved
therapeutic strategies. Proper glycemic control and attainment
of other nonglycemic management targets (e.g., blood
pressure, lipids, body weight) are essential to the prevention
of long-term complications of diabetes and to the reduction of
overall disease management costs. Two prime examples
of such therapy are treatment of hypertension and early stages
of diabetic renal dysfunction with antihypertensive agents,
and specifically with angiotensin-converting enzyme inhib-
itors, and laser photocoagulation of proliferative retinopathy
and clinically significant macular edema. The latest American
Diabetes Association (ADA) guidelines recommend a range
of interventions to better improve type 2 diabetes outcomes by
controlling the multiple coexisting complications associated
with this chronic, progressive disease (Table 1) [13].
I. Type 1 diabetes
Type 1 diabetes is a metabolic disorder that results from the
progressive destruction of insulin-secreting β-cells in the
islets of Langerhans of the pancreas, leading to insulin
insufficiency and hyperglycemia [14]. People with type 1
diabetes are dependent on insulin for the rest of their life.
But insulin is not a cure, and people with diabetes are at
significant risk for a wide range of serious complications,
including heart and kidney diseases and blindness [15].
To avoid the variations in blood glucose levels in those
with type 1 diabetes, and to reduce the chance of long-term
complications, it would be helpful for new β-cells to be
produced. Ideally, new β-cells should be derived from cell
sources already existing within the person with diabetes so
avoiding immunosuppression [16]. Alternatively exogenous
sources of surrogate β-cells have also been described,
including adult human pancreases donated after death, fetal
pancreas, pluripotent and multipotent stem cells, and cells
that reside in the liver. Whilst most of these exogenous
sources are heterologous to the recipient; some are
autologous such as cord blood stem cells and pluripotent
stem cells induced from fibroblasts derived from skin [17].
Transplantation of human pancreatic tissue derived after
death is the alternative therapy currently available that
allows the possibility of even transient cessation of
exogenous insulin.
Glycosylated hemoglobin <7% (as close to 6% as possible for each individual patient)
Preprandial plasma glucose 90–130 mg/dl (5.0–7.2 mmol/L)
Postprandial plasma glucose <180 mg/dl (<10 mmol/L)
Blood pressure <130/80 mmHg
Low-density lipoprotein cholesterol <100 mg/dl (<2.6 mmol/L)
High-density lipoprotein cholesterol >40 mg/dl (>1.1 mmol/L)
Triglycerides <150 mg/dl (<1.7 mmol/L)
Body mass index <25.0 Kg/m2
Table 1 American Diabetes
Association—recommended
therapeutic goals for
patients with type 2
diabetes [13]
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Pancreas transplantation
There has been a great deal of excitement and investigation
in islet transplantation, but at the current time only whole-
organ pancreas transplantation can be counted on for long-
term exogenous insulin independence and normalization of
HbA1C. The majority of pancreas transplants are simulta-
neous pancreas-kidney transplantation, the preferred treat-
ment option for diabetics with approaching or coexisting
end-stage renal disease [18]. The benefits of pancreas
transplantation are clear: improved quality of life, preven-
tion of recurrent diabetic nephropathy, freedom from
exogenous insulin with euglycemia and normalization of
HbA1C, less stringent dietary restrictions, less frequent
blood glucose monitoring and stabilization of or improve-
ment in secondary complications. The major disadvantages
to the patient are the operative risk, the need for chronic
immunosuppression, and the inherent side effects of
chronic immunosuppression [19].
Islet transplantation
A promising way of treatment of diabetes is using β-cell
replacement therapy. Significant advances in islet isolation
techniques have allowed progress in research using trans-
planted human islets [20].
Enthusiasm for the promise of human islet transplanta-
tion started in 2000 with the publication of the Edmonton
protocol (Fig. 1). Because many traditional immunosup-
pression regimens were known to be toxic to islets, Shapiro
et al. [21] employed a modified immunosuppression
protocol with a monoclonal antibody against interleukin 2,
daclizumab, and eliminated glucocorticoids. Notably, both
host-versus-graft and autoimmune reactions were avoided.
However, despite short term success, long term insulin
independence is usually unsustainable. Several follow-up
studies indicate that even with the rigorous application of
steroid-free immunosuppressive regimens, only 14% of the
patients maintained insulin independence at 2 years, and
30% had complete graft loss 1 year after the final
transplantation [22–24]. It was noteworthy that 80% of
patients evaluated had a “good metabolic outcome,” which
was defined as decreased insulin requirements and fewer
hypoglycemic events 2 years after transplant.
The Edmonton protocol is limited by several major
factors: the lack of a sufficiently large source of islets due
to the scarcity of cadaveric pancreas donors, and the
presence of persistent immune rejection as well as the
potential for recurrence of autoimmunity. There is still a
slow and progressive loss of insulin production from
transplanted islets in diabetic recipients over time, as
evidenced by reports that 30–40% of islet recipients may
experience recurrence of autoimmune diabetes with re-
acquisition of insulin dependence 1 year to 2 years post
transplantation [21, 24]. A third limiting factor is islet
revascularization, which appears to play an important role
in determining the long-term survival and optimal perfor-
mance of functional islet mass post transplantation. Rapid
re-establishment of an appropriate microvascular system in
newly transplanted islets is crucial for survival and function
of islet grafts. Unfortunately, islets implanted at ectopic sites,
such as under the renal capsule or in the liver and spleen, are
invariably associated with markedly reduced vascularization,
in comparison with native islets in the pancreas [25, 26]. This
impairment in islet revascularization accounts at least in part
for the demand of sufficiently large quantities of islet mass
for restoration of normoglycemia in type 1 diabetic subjects.
In addition, delayed and inadequate islet graft vascularization
can deprive islets of oxygen and nutrients, causing islet cells
to undergo cellular apoptosis and subsequent cell death,
particularly in the core of large islets or in the center of
aggregated islet clusters post transplantation. Moreover, a
lack of sufficient islet revascularization may also compro-
Fig. 1 The process of islet
transplantation (illustration by
Giovanni Maki) [32]
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mise the optimal performance of transplanted islets. Indeed,
there are clinical data indicating that even after postabsorp-
tive blood glucose homeostasis is restored to normal post
islet transplantation, implanted islets do not seem to function
at optimal levels, as reflected in their significantly impaired
glucose tolerance in diabetic recipients in response to
intravenous glucose challenge [24, 27]. Thus, it is of great
significance to define the molecular mechanism of islet
revascularization and develop therapeutic angiogenesis
approaches to enhance the process of islet revascularization.
Such approaches are expected to ensure adequate microvas-
cular perfusion to islet cells and protect implanted islet cells
from hypoxia-induced inflammation and necrosis, which will
ultimately improve the outcome of islet transplantation by
reducing the donor/recipient ratio thus increasing the success
rate of islet transplantation [28]. Antioxidant supplementa-
tion [29, 68], elevation of vascular endothelial growth factor
(VEGF) delivery [30] to islet grafts and co-transplantation of
bone marrow-derived mesenchymal stem cells [31] improves
the outcome of islet transplantation by enhancing islet
revascularization.
Many other interventions are being tested to improve islet
survival, such as the use of growth factors [62], glucagon-like
peptides (GLP) and GLP-1 analogs [63], oxygen carriers
[64], substances that reduce inflammatory response [65],
anticoagulants [66] and antiapoptotic drugs [67].
The limitations and long term failure of the early
transplantation therapies indicate that the procedure in its
current format is not suitable for all patients with type 1
diabetes [69]. Intensive research is being conducted to look
for alternative sources of β-cells.
An alternative to avoiding immunosuppression is to
deliver encapsulated islets; immobilized in selectively
permeable casings, islets would be capable of sensing
glucose and secreting insulin but would be protected from
immune attack. In theory, these membranes would permit
islet transplantation without immunosuppression and would
also make xenotransplantation a viable option, potentially
solving the problem of donor scarcity by making use of
more abundant sources such as porcine islets [33, 34].
Microencapsulation strategies have been used successfully
in animal studies; the delivery of bovine islets packaged in
alginate gel spheres to the peritoneum of rats has been
shown to normalize STZ-induced hyperglycemia [35].
Although complications with vascularization and fibrosis
around encapsulated islets have not been totally resolved,
clinical trials for encapsulated islet delivery to type 1
diabetics are moving forward [36].
Thus, the development of alternative sources of islets,
such as the promotion of transdifferentiation of nonbeta
cells into an insulin-secreting phenotype, may be a viable
option (Fig. 2). In addition, advances in the understanding
of pancreas development have already informed the
development of techniques to direct the differentiation of
stem cells toward endocrine cells.
Stem cells
An alternative resource for transplantable β-cells is the
stem cell. Stem cells are cells that are able to proliferate
while maintaining an undifferentiated status (self-renewal)
and retaining a capacity to differentiate into specialized cell
types under appropriate conditions. The sources of such
stem cells for the purpose of generating β-cells were firstly
identified through several studies on adult and fetal
pancreas. There are two potential sources of stem cells:
embryonic stem cells (ES) [47] and the new induced
pluripotential stem cells that are reprogrammed from
mature adult cells by transduction with transcription factor
DNA or recombinant transcription factor proteins [37].
Recently, Kroon et al. [38] reported the development of
functional islet-like structures in mice transplanted with
human ES cell-derived pancreatic endoderm. Unfortunately,
in addition to the generation of functional β-cells in the vast
majority of transplant recipients, Kroon et al. also observed
teratoma formation in a small number of cases. This
outcome highlights the delicate balance between the risks
and benefits that will need to be managed in future stem
cell replacement therapies.
New technologies for reprogramming of adult cells to an
induced pluripotent state (iPS), similar to ES cells, may
change the landscape of future β-cell therapy [39–43].
Theoretically, it should become straightforward to make
autologous iPS cells starting with readily accessible skin or
blood cells from any individual, and to use these as a source of
transplantable cells, obviating the need for immunosuppres-
sion. At a practical level it is not clear that this degree of
individualized medicine can be made cost effective for patient
populations. However, assessments of cell banking strategies
have indicated that as few as ten pluripotent cell lines carefully
chosen for homozygosity of the most common alleles at the
major histocompatibility genetic loci would provide consid-
erable practical benefit for transplantation matching [44].
It remains to be shown that iPS cells have the same
capacity as human ES cells for differentiation toward β-
cells. However, a very recent report documents that human
iPS cells, indeed, give rise to insulin-producing cells [45].
The iPS cells were induced to yield pancreatic islet-like
clusters using one of the culture protocols previously
described for human ES cells.
The recent demonstration that human somatic cells can
be reprogrammed to a pluripotent stem cell fate suggests
that ethical and legal issues will need to be circumvented
[41, 46]. Two groups of investigators used genes known to
be enriched in ES cells and involved in the establishment of
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pluripotency to reprogram human somatic cells. Using
slightly different protocols, both groups established plurip-
otent lines that were capable of differentiating into all three
germ layers and forming teratomas when injected into mice.
The limitations of this finding are considerable, given that
the reprogramming involved the use of viruses and the
expression of the proto-oncogene c-Myc. However, alter-
native methods of cell transduction can be developed and
somatic cell-derived insulin-producing cells for diabetes
therapy may be possible in the not too distant future.
It is noteworthy that Dr. Nagy and co-workers discov-
ered a new method to create pluripotent stem cells without
disrupting healthy genes [48]. This method uses a novel
wrapping procedure to deliver specific genes to reprogram
cells into stem cells. Previous approaches required the use
of viruses to deliver the required genes, a method that
carries the risk of damaging the DNA. This new method
does not require viruses, and so overcomes a major hurdle
for the future of safe, personalized stem cell therapies in
humans. This study accelerates stem cell technology and
provides a road map for new clinical approaches to
devastating diseases such as diabetes.
In a 2007 Brazilian study [49], a small number of people
newly diagnosed with type 1 diabetes were able to stop using
insulin after being treated with stem cells made from their
own blood. Although stem cell transplants, which involve
shutting down the immune system and then building it up
again, can be risky though the technique may 1 day provide
an additional treatment option for type 1 diabetes [49, 202].
More recently a pilot study has shown that transfusion of
umbilical cord blood in children with type 1 diabetes may
decelerate the loss of endogenous insulin production [61].
The experimental challenge in the future will be to unravel
the optimal cell source; but there is growing reason for
optimism in the replacement of islet transplantation from
deceased organ donors by stem cell-derived highly func-
tional β-cells as an achievable goal.
Transdifferentiation
Another method of β-cell replacement for diabetes
therapy might involve gene transfer or growth factor







of ES Cells 





Fig 2 Sources of new β-cells for the treatment of type 1 diabetes.
Type 1 diabetes results from the autoimmune destruction of pancreatic
β-cells. A cure for the disease may lie in the development of
techniques to replenish islet mass. Some researchers have already
directed the differentiation of ES cells toward an endocrine (Ins+) cell.
The potential exists for liver and nonendocrine pancreatic cells to be
reprogrammed by gene transfer or growth factor treatments to produce
and release insulin in response to glucose. Recent evidence has
suggested that adult β-cells are mitotically active and can replicate in
response to increasing insulin demands. A complete understanding of
the factors and signals that regulate this process could allow this
innate ability to be controlled in patients with diabetes. Finally,
cadaveric human islets represent a promising source of therapeutic β-
cells through transplantation. Immunofluorescence staining of a
primary adult mouse islet is shown in the center (insulin appears
red). Abbreviations: DE, definitive endoderm; ES, embryonic stem;
Ins+, insulin-positive
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insulin and respond to changes in extracellular glucose.
Given the close embryonic origins of the pancreas and
liver, some investigators have focused efforts on trans-
differentiation of the liver to a pancreatic endocrine cell
fate. Ferber et al. [50]. demonstrated that adenoviral-
mediated expression of PDX1 induced insulin expression
in the liver and rescued STZ-induced hyperglycemia in
mice. Although the reprogramming of liver or exocrine
tissue to pancreatic endocrine cell fates rescues mouse
models of hyperglycemia, the application to human
disease may be limited by ongoing autoimmune attack
on the β-cells of patients with type 1 diabetes face [51].
Insulin-producing cells in the liver might also be suscep-
tible to autoimmune lymphocyte infiltration and apoptosis.
Offering some optimism in this regard, Shternhall-Ron
and co-workers [52] recently demonstrated that adenovir-
ally delivered PDX1 rescued glucose tolerance in
cyclophosphamide-accelerated nonobese diabetic mice.
The potential for gene therapy is enormous. For instance,
gut K cells of the mouse were induced to produce human
insulin by transfecting the human insulin gene linked to the 5′-
regulatory region of the gene encoding glucose-dependent
insulinotropic polypeptide (GIP) [53]. Also, research dem-
onstrating that hepatocytes transfected with the PDX1 gene
under the control of the rat insulin 1 promoter were able to
produce insulin [50, 54] attracted significant attention and
has inspired new hope. In these studies, sufficient levels of
insulin were secreted to satisfy the needs of a diabetic
mouse, which, when treated, became and remained steadily
euglycemic. These studies, however, have not yet been
successfully repeated by other groups. This finding suggests
that gene therapy-mediated transdifferentiation may prove to
be a viable strategy for producing new β-cells, despite
ongoing autoimmune attack (see section IV).
It has recently been shown that infecting liver with a
virus containing the gene for neurogenin, a transcription
factor that is expressed as cells begin differentiating into
insulin-producing β-cells, cells in the liver can take on the
function of pancreatic cells and go on to reverse symptoms
of diabetes in a mouse model of the disease [55]. Other
researchers showed that adding genes for transcription
factors can change cell differentiation [56].
Prevention and early intervention
In humans, the accumulation of islet antibodies with
differential specificities for β-cell proteins, in combination
with genotyping for susceptibility alleles, can predict the
risk to develop clinical diabetes. However, researchers are
still unable to arrest β-cell destruction in pre-diabetic
patients, even though a lot of evidence collected from
preclinical studies using various therapeutic regimens in
different animal models for type 1 diabetes has been
successful in preventing type 1 diabetes [57]. Some
compounds (anti-CD3 antibodies, glutamic acid decarbox-
ylase (GAD) of 65 kDa [GAD65], Diapep277, and anti-
thymocyte globulin) that reestablished long-term tolerance
in animal models after new-onset type 1 diabetes show
promising effects in reducing β-cell decline in phase I and
II clinical trials in humans with recently diagnosed type 1
diabetes, but none of them was able to cure the disease [58,
60]. Other antigen non-specific agents, such as the anti-
thymocyte globulin and monoclonal anti-CD20 antibody
(Rituximab) (http://diabetestrialnet.org), are currently under
trial in recent-onset type 1 diabetes [57, 60].
The GAD-based diabetes vaccine for type 1 diabetes has
been demonstrated to slow or arrest the destruction of
insulin producing β-cells, which is characteristic of
autoimmune diabetes. Studies have demonstrated that the
Diamyd® vaccine is most efficacious early in the disease
process, in recent-onset type 1 diabetes patients. Diamyd
Medical is currently conducting two clinical Phase III
studies on type 1 diabetes: one in Europe and one in the
United States. These studies apply to people diagnosed with
type 1 diabetes within the past 3 months. Prevention studies
have already been initiated, where researchers intend to
evaluate the Diamyd® vaccine in children and adults at risk
of developing type 1 diabetes [59]. When people are first
diagnosed with type 1 diabetes, they still have cells that
produce insulin. Diamyd® treatment is intended to halt or
slow the autoimmune destruction process and save the
remaining β-cells. Diamyd can also be combined with other
drugs that stimulate the generation of new β-cells, or with
β-cell transplants.
II. Type 2 diabetes
Type 2 diabetes mellitus is a multifactorial metabolic
disorder characterized by chronic hyperglycemia due to
relative or absolute lack of endogenous insulin. Patients
have elevated fasting and postprandial plasma glucose
levels. Type 2 diabetes development appears to involve
defects in insulin action and secretion [70]. Type 2 diabetes
is the result of a combined defect in insulin resistance, β-
cell dysfunction, increased hepatic glucose dysfunction, and
reduced glucagon-like peptide 1 (GLP-1) levels [70–72].
Glucose levels remain normal or only mildly impaired
when islet β-cells remain able to compensate with
sufficient insulin output to overcome insulin resistance
(IR). A progressive decline in β-cell compensation in a
subset of insulin-resistant subjects eventually leads to overt
hyperglycemia. IR affects the main insulin target tissues,
namely, skeletal muscle, liver, and adipose tissue. The
progressive loss of β-cell function and increased IR may be
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due to a number of factors such as genetic abnormalities
and acquired defects. Although a degree of IR may be
inherited, it may progress with additional factors such as
obesity and a sedentary lifestyle. hyperglycemia can worsen
IR and insulin secretion because of effects such as
decreased effective responsiveness of β-cells and decreased
sensitization to insulin of target tissues [73].
IR is likely due to the interplay of genetic factors,
modifications to the insulin signalling pathway, and
inflammation. Insulin secretion is affected by multiple
factors, including the baseline secretion capacity, incretin
effect, nutrient excess of glucose and free fatty acids
(FFAs), and amyloid deposition [73, 74].
Treatment of type 2 diabetes has centered on (1)
increasing insulin levels, either by direct insulin administra-
tion or oral agents that promote insulin secretion (insulin
secretagogues, such as oral sulfonylureas), (2) improving
tissue sensitivity, such as with insulin sensitizer biguanide
metformin or thiazolidinediones (TZDs), or (3) reducing the
rate of carbohydrate absorption from the gastrointestinal
tract by the use of α-glucosidase inhibitors or agents that
decrease gastric motility. Progressive β-cell dysfunction and
β-cell failure are fundamental pathogenic features of type 2
diabetes, and, ultimately, the development and continued
progression of diabetes is a consequence of the failure of the
β-cell to overcome insulin resistance. Current therapies
become less effective over time as a result of progressive loss
of β-cell function and number, with the result that a majority
of type 2 diabetic patients do not achieve current glycemic
goals as reflected by HbA1c greater than 7% in more than
60% of treated patients [7, 8, 75–78].
Conventional therapies
Diet and exercise are the first step of therapy for type 2
diabetes; if these do not keep blood sugar at goal levels,
then antihyperglycemic agents are added. Drug therapy for
type 2 diabetes aims to control blood sugar levels both in
the basal (fasting) state and postprandially; rational combi-
nations of agents with different mechanisms of action can
be used (Fig. 3).
Delay of gastric emptying 
Inhibition of glucagon release 
Inhibition of glucose absorption 
Stimulation of GLP-1 release 
Acute stimulation of insulin release
Stimulation of insulin biosynthesis 
Inhibition of β-cell apoptosis   
Stimulation of β-cell differentiation  
Inhibition of hepatic glucose production
Increase in hepatic insulin sensitivity 
Increase in muscle insulin sensitivity 
Suppression of FFAs release 
Fat redistribution (visceral to subcutaneous) 








Tissue site Mechanism Drug 
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Fig. 3 Pharmacological treat-
ment of hyperglycemia according
to site of action. GLP-1—gluca-
gon-like peptide 1. DPP
4—dipeptidyl peptidase 4.
FFAs—free fatty acids. Adapted
from Stumvoll et al. 2005 [73]
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Four major classes of antihyperglycemic agents can be
used, either as monotherapy or, more appropriately, in





Insulin secretogogues correct hyperglycemia by stimu-
lating insulin secretion—but only if the patient still has
enough functioning β-cells. They close ATP-sensitive
potassium channels in the β-cells of the pancreas, increas-
ing insulin production; slow-acting and rapid-acting agents
are available. The major side effects of insulin secreto-
gogues (and insulin replacement) are hypoglycemia and
weight gain.
Sulfonylureas are insulin secretagogues, enhancing
insulin secretion by binding to a unique receptor on
pancreatic β-cells and having their greatest effect on fasting
hyperglycemia [79, 80]. In this group we can include the
second-generation agents gliclazide, glyburide, and glime-
piride, as well as the first-generation agents acetohexamide,
chlorpropamide, tolazamide, and tolbutamide. When used
as monotherapy, sulfonylureas generally result in HbA1C
improvements of a magnitude similar to metformin (1.5%)
[80]. Sulfonylureas are commonly associated with hypo-
glycemia and weight gain (∼2 kg). Based on long
experience, efficacy, and low cost, sulfonylureas are
recommended by the ADA-EASD as options for second-
step pharmacotherapy in patients whose HbA1C remains
elevated on metformin [80].
However, sulfonylureas are also hindered by limited
durability of effect, with 3- and 9-year failure rates similar
to those described for metformin [76], which is again
consistent with progressive β-cell failure [81]. It has been
previously described that gliclazide improves vascular
activity decreasing oxidative stress and inflammation.
Gliclazide, the main drug used in the ADVANCE study
[91], may also be potentially beneficial in abolishing the
“metabolic memory”.
Meglitinides The recently introduced class of megliti-
nides consists of nateglinide, which binds to the same site
of sulphonylurea receptor 1 as do the sulfonylurea
derivatives, and repaglinide, which binds to a nearby site
of the receptor, both leading to insulin release. They
stimulate rapid, short-lived, insulin secretion [82]. They
lower postprandial glucose levels, although fasting hyper-
glycemia is also improved. Meglitinides are more specific
that sulfonylureas and are associated with lower risk of
hypoglycemia but clinical experience remains limited.
These agents cannot further stimulate insulin release in
patients on maximal doses of sulfonylurea derivatives.
These drugs can be used in patients with decreased renal
function [83] and for individuals with varying daily meal
patterns. Experimental evidence suggests a better preserva-
tion of β-cell function compared to sulfonylureas [84] and
improved vascular effects that remain to be clinically
proven [85]. The NAVIGATOR (Nateglinide and Valsartan
in Impaired Glucose Tolerance Outcomes Research) study
aims to assess the utility of these drugs in prevention of
diabetes and their impact on cardiovascular morbidity and
mortality.
Metformin, is an insulin sensitizer well accepted as a
first-line agent for treatment of type 2 diabetes [80]. It is a
biguanide derivative that exerts an antihyperglycemic effect
with minimal risk of hypoglycemia. Metformin lowers
blood glucose concentration and improves insulin sensitiv-
ity by reducing hepatic gluconeogenesis and enhancing
insulin-stimulated peripheral glucose uptake [79, 80]. In
addition, metformin reduces insulin resistance in muscle
tissue and the liver, decreasing postprandial hyperglycemia
and inhibits adipose tissue lipolysis thereby reducing
circulating levels of FFAs [79, 86]. Metformin may also
suppress inflammation independently of action on glucose,
insulin and FFAs [88]. When used as monotherapy,
metformin typically reduces HbA1C by about 1.5% [80].
Metformin also improves the lipid profile and lowers blood
pressure and plasminogen activator inhibitor- 1 levels in
both patients and animals with impaired glucose tolerance
and type 2 diabetes [8, 86, 87]. In overweight type 2
diabetic patients, metformin use is associated with
decreases in macrovascular morbidity and mortality, effects
that appear to be independent of the improvement in
glycemic control [8, 86, 92, 93].
Caution must be exercised when using metformin in a
number of other patient populations, including those with
impaired hepatic function or requiring drug therapy for
heart failure, and metformin should be temporarily discon-
tinued prior to surgical procedures or intravascular radio-
contrast studies [89]. In addition, metformin has been
associated with rare cases of fatal lactic acidosis and is
contraindicated in patients with renal dysfunction [89].
Furthermore, a study by Ting et al. noted that metformin
use was associated with a risk of vitamin B12 deficiency
[90]. The frequency of gastrointestinal adverse events may
limit the ability to reach maximally effective doses, with
rates of diarrhea and nausea/vomiting of up to 53% and
26% of patients, respectively [89]. Because of its efficacy,
infrequency of weight gain or hypoglycemia, and low cost,
metformin has been recommended by the ADA-EASD as
first-line pharmacotherapy for type 2 diabetes [80]. How-
ever, the durability of metformin’s effectiveness as mono-
therapy is limited consistent with the progressive loss of
β-cell function seen in type 2 diabetes [81].
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Thiazolidinediones, another class of insulin sensitizers,
currently include pioglitazone and rosiglitazone. They
enhance insulin sensitivity reducing hyperglycemia and
ameliorating the dyslipidemia and inflammatory milieu of
type 2 diabetes [94]. TZDs improve insulin sensitivity in
muscle and adipose tissue and in the liver by activating
peroxisome proliferators activated receptor -γ (PPAR-γ)
[79, 80, 95]. TDZs alter adipose metabolism and distribu-
tion and redistribution of tissue triglyceride from visceral
stores, reducing levels of circulating FFAs apparently by
sequestration in a less lipolytic subcutaneous compartment
[96]. TDZs also reduce circulating concentrations of pro-
inflammatory cytokines that promote insulin resistance (eg,
tumor necrosis factor-α and interleukin 6) and at the same
time increase concentrations of adiponectin, which has
insulin-sensitising and anti-inflammatory properties. TZDs
have also been shown to improve β-cell function, probably
as a result of PPAR-γ-mediated decreases in insulin
resistance and β-cell fatty acid concentrations [95]. TZDs
have demonstrated the ability to conserve β-cell function,
delaying or preventing the development of type 2 diabetes
in a high-risk population of women with gestational
diabetes in the TRIPOD (TRoglitazone In the Prevention
Of Diabetes) and PIPOD (Pioglitazone In the Prevention Of
Diabetes) studies [97, 98]. A large number of studies show
that the TZDs are effective as monotherapy or in combi-
nation with metformin, sulfonylureas, and insulin in the
treatment of type 2 diabetes. When used as a single agent,
TZDs decrease HbA1C in the range of 1.0–1.6% and have
a lower incidence of treatment failure than with metformin
or the sulfonylurea, glyburide [99–101]. However, the
TZDs are more effective when used in combination with
metformin, sulphonylureas, or insulin [102–104]. The
TZDs should not be given to patients with heart failure
because they typically cause fluid retention and peripheral
edema, worsening heart disease [105, 106].
The multiple effects of thiazolidinediones on adipose
tissue metabolism and cross-talk of these signals with liver
and skeletal muscle, as well as pancreatic β-cells and the
vascular endothelium, might account for the enhancement
of insulin action and improvement in insulin secretion with
these agents, as well as several beneficial effects on
vascular function [107]. Renal and vascular benefits of
thiazolidinediones have been demonstrated in controlled
studies, for example, showing significant improvement in
albumin excretion above that observed with a similar
degree of glycemic lowering with sulfonylureas [108].
Unlike metformin, the thiazolidinediones can be used in
patients with reduced renal function, and they are better
tolerated without significant gastrointestinal side effects. A
major adverse effect associated with clinical use of the
thiazolidinediones is weight gain, which seems to be
coupled to the effects of the drugs on adipose cell
differentiation and triglyceride storage. Fluid retention is
also linked to the PPARγ-agonist activity of the thiazolidine-
diones, leading to peripheral oedema and a mild hemodilution
in some patients [105, 109]. Fortunately, congestive heart
failure is quite rare with use of thiazolidinediones, but
remains a serious concern [110]. TZDs may cause hepato-
toxicity and should not be used in patients with impaired
liver function [111]; the U.S. Food and Drug Administration
(FDA) recommends regular liver-function testing in all
patients on TZDs. The use of TZDs has also been reported
to (1) increase the risk of myocardial infarction and other CV
diseases [112, 113], (2) decrease bone formation, accelerate
bone loss, and increase the risk of fractures [114, 115], and
(3) induce macular edema [116]. The ability of thiazolidine-
diones to ameliorate risk of atherosclerotic events is being
assessed in several large outcomes studies.
TZDs are recommended by the ADA-EASD as an
alternative agent in second-step therapy after metformin
failure [80]. Although more expensive than generic ver-
sions of metformin and sulfonylureas.
α-glucosidase inhibitors
The α-glucosidase inhibitors, acarbose, miglitol and vogli-
bose, slow digestion of oligosaccharides, thereby providing
an alternative to reduce postprandial glucose levels [117].
The α-glucosidase inhibitors do not cause weight gain, can
reduce postprandial hyperinsulinemia, and have been
shown to lower plasma triglyceride levels in some studies
[118]. They must be dosed multiple times per day and are
associated with frequent gastrointestinal side effects [80].
They generally have less potent glucose-lowering effects
than other oral anti-diabetics [80]. In the STOP-NIDDM
(Study to Prevent Non-Insulin Dependent Diabetes Mellitus)
trial, acarbose reduced the incidence of new cases of type 2
diabetes in high-risk subjects with impaired glucose toler-
ance [119]. Acarbose therapy is also associated with a
reduction in incidence of cardiovascular events [120]
although some controversy is present.
Insulin
Several different insulin analogs are available for type-1
and advanced type-2 diabetic patients. The injected insulin
types differ in their onset and duration. Insulin therapy
often has two components, an intermediate acting or long-
acting insulin given at bedtime, and a rapid-acting insulin
given before meals [121].
Insulin administration is the most effective means of
restoring glycemic control; because there is no maximum
dose, any HbA1C level can be reduced to the target range if
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insulin is dosed adequately [80]. However, insulin has a
number of limitations. It is typically administered by
subcutaneous injection, often requiring multiple injections
per day. Insulin carries a tangible risk of hypoglycemia, and
regular self-monitoring of blood glucose is usually required
[80]. It is typically associated with weight gain that
significantly increases in patients on intensive insulin
therapy [122] with adverse cardiovascular consequences
[98]. The ADA-EASD guidelines recommend addition of
insulin as a second-step option for patients who are not
adequately controlled on metformin monotherapy or as a
third-step option for patients who still do not reach the
HbA1C target goal on oral combination therapy [80].
Insulin is also the treatment of choice for patients with
severely uncontrolled or symptomatic type 2 diabetes [80].
Novel antidiabetic agents
The currently available therapies used for type 2 diabetes
do not significantly improve β-cell function. In addition,
the current approach does not address defects in hormonal
secretion thought to play key roles in the pathophysiology
of type 2 diabetes.
New emerging therapies for type 2 diabetes have become
available in some countries in recent years (Table 2). As a result
of their recent availability, long-term studies are lacking and
full safety profiles of these compounds are largely unknown,
even though they are being used in large numbers of patients.
These drugs offer a range of different mechanisms of
action that complement established therapies (Fig. 3).
Several of the novel drugs are based on the incretin
hormone, GLP-1. GLP-1 controls glucose levels through
various mechanisms including glucose-mediated insulin
secretion, suppression of inappropriate glucagon release,
slowing gastric emptying and increasing satiety [124–126].
The natural hormone is rapidly degraded by the enzyme
dipeptidyl peptidase 4 (DPP-4), and the two approaches to
new agents are inhibitors of DPP-4 activity and develop-
ment of GLP-1 analogues resistant to degradation. An
important property of these agents is their neutral or
beneficial effect on bodyweight [127].
Incretin system
Gastrointestinal polypeptide hormones that are secreted in
response to ingestion of a meal augment postprandial insulin
secretion; this is known as the incretin effect and can account
for up to 70% of postprandial insulin secretion [128]. The two
most important incretin hormones are GLP-1 and GIP; these
hormones are secreted by the L cells of the distal ileum and
colon, and the K cells of the duodenum and upper jejunum,
respectively. Circulating concentrations of incretins rise
within minutes of eating, implying likely stimulation via
activation of neuro-endocrine pathways. Incretins act via
specific G-protein-coupled receptors on β-cells to enhance
glucose-stimulated insulin secretion [129].
The incretin effect is almost completely deficient in
patients with type 2 diabetes, mainly because of reduced
postprandial GLP-1 secretion that is accompanied by a
markedly reduced insulinotropic action of GIP [130].
Investigators have observed that infusing GIP or GLP-1
into patients with type 2 diabetes recovers the first phase
insulin response, and this indicates an improvement in β-
cell function. In animal models, it has been suggested that
GLP-1 stimulates neogenesis of β-cells and inhibits β-cell
apoptosis. Thus, agents that increase the GLP-1 signal raise
the intriguing possibility of replenishing endogenous
insulin by increasing the β-cell population, potentially
preventing or even reversing disease progression.
Novel therapies that exploit the incretin effect of GLP-1
include the injectable incretin mimetics and the orally
active DPP-4 inhibitors. Their development arose from the
understanding and extensive research into incretin physiol-
ogy and metabolism.
GLP-1 receptor agonists
The only GLP-1 receptor agonist currently available is
exenatide, although a second agent, liraglutide, is in late-
phase clinical development [133]. These agents are not
effective orally and require administration by subcutaneous
injection. In clinical trials, they lowered HbA1C concentration
by 0.5–1.0% and had the additional advantage in producing a
significant weight loss. The current indication for these drugs
is for use after patients have experienced failure of glycemic
control with metformin, sulfonylureas and/or TZDs [125, 131,
132]. Exenatide has been evaluated as an alternative to insulin
in patients with type 2 diabetes who have inadequate
glycemic control. It leads to weight loss, at least over a 3-
year period. Long-acting forms of once-weekly injection, such
as exenatide LAR, are under development. When used in
combination with metformin, sulfonylureas, TZDs, or
metformin plus a sulfonylurea, exenatide has been shown
to result in weight loss (0.9–2.8 kg) [134]. Daily liraglutide
therapy had similar effects with respect to blood glucose
control, β-cell function, and weight loss as twice-daily
exenatide, and its effects were sustained for at least 1 year.
These agents are not generally associated with
hypoglycemia but a large proportion of treated patients
experience nausea and vomiting, although these gastro-
intestinal adverse effects tend to become less over time.
There have been some recent reports of hemorrhagic or
necrotizing pancreatitis and patients should be monitored
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for signs and symptoms [135]. Exenatide is not recom-
mended for patients with severe renal impairment.
Dipeptidyl peptidase 4 inhibitors
Pharmacological inhibitors of DPP-4 are orally active
agents that acutely increase postprandial plasma levels of
endogenous GLP-1 typically 2-fold. In contrast with
incretin mimetics, and perhaps reflecting the relatively
modest increases in incretin levels, DPP-4 inhibitors show
little or no evidence of a deceleration in gastric emptying
[136], and mild gastrointestinal adverse effects.
There are two DPP-4 inhibitors currently available, which
are sitagliptin, available in Europe and the USA, and
vildagliptin, currently only available in Europe; both are
orally active small molecules that result in increased incretin
hormone activity. In clinical trials of these agents, HbA1C
concentration was reduced by 0.5–0.9%, and bodyweight was
not significantly altered. They may be used either as
monotherapy or in combination with metformin or sulfony-
lureas. When used as monotherapy, they are generally not
associated with hypoglycemia. DPP-4 is found in many
tissues throughout the body and there are a large number of
potential substrates [194]. As a result, DPP-4 inhibitors can
affect many processes that may lead to side effects; for
example, they may interfere with the immune system and
side effects of upper respiratory tract infections have been
reported [194]. While these drugs are being used increasingly
and frequently, data on long-term use are lacking and the
continued safety profile remains to be established. We do not
yet know whether these new agents will have significant,
long-term disease-modifying effects.
Sitagliptin is a well tolerated, orally administered inhibitor
of DPP-4, the enzyme responsible for rapid degradation of
GLP-1 [129, 130, 201]. DPP-4 inhibitors improve glycemic
control by increasing levels of biologically intact GLP-1,
resulting in a reduction in hepatic glucose output and
increase in insulin production. Due to its mechanism of
action, it has been suggested that DPP-4 may potentially
improve β-cell function in humans. In addition, these agents
appear to be weight neutral when used as monotherapy or in
combination with other agents [195].
DPP-4 inhibitors would almost certainly be more useful
in type 2 diabetes management if used in addition to agents
that would increase incretin secretion (incretinotropics).
Metformin actually increases incretin secretion [196], and
this factor probably explains why the addition of DPP-4
inhibitors to metformin therapy has a synergistic effect on
reductions in HbA1C more pronounced than simply adding
together the effects of each as a monotherapy: metformin
prevents the negative feedback of DPP-4 inhibition on
incretin secretion.
Pramlintide
Amylin (islet amyloid polypeptide) is a 37-aminoacid
peptide hormone that is co-secreted with insulin from islet
β-cells in response to meals [197]. The hormone acts
centrally via the area postrema and other regions to activate
neural pathways that decrease glucagon release from
pancreatic α-cells [198] and slow gastric emptying [199],
contributing to a glucose-lowering effect. Amylin also
appears to act centrally to promote satiety, thereby reducing
caloric intake [200]. Human amylin precipitates and
aggregates to form amyloid fibres, which play a putative
role in the progressive β-cell destruction [197].
Pramlintide, a human amylin analogue, is currently only
approved for use in the USA and as an adjunct to insulin
therapy [137, 138]. It is administered by subcutaneous
injection before meals and decreases post-meal glucose
excursions by slowing gastric emptying and reducing
glucagon secretion in a glucose-dependent manner. Clinical
trials showed a relatively small reduction in HbA1C of 0.5–
0.7%, although there was also a decrease in body weight of
approximately 1–1.5 kg over 6 months, despite the
concomitant treatment with insulin. The weight reduction
was most likely caused by the satiety effect.
The α-glucosidase inhibitors, pramlintide, and DPP4
inhibitors generally result in smaller reductions in HbA1C
when compared with other treatment options recommended
by the ADA-EASD [129, 130]. A comparison of available
glucose-lowering agents is presented in Table 3.
Incretin-based therapies give new options for lowering
blood glucose and should be placed alongside, and added
to, older options. No data are yet available on whether these
new agents affect hard endpoints such as cardiovascular
disease, morbidity, and mortality.
Although several classes of anti-diabetic drugs are
available, achieving and maintaining long-term glycemic
control is often challenging, and many current agents have
treatment-limiting side effects. So, a significant need for
novel therapeutical approaches remains.
Bariatric surgery
The use of bariatric surgery to achieve and maintain weight
loss and ameliorate or resolve diabetes is generating great
interest in light of the current epidemic of obesity and
diabetes worldwide. Bariatric surgery is recognized as the
most effective therapy for treating severe obesity and its
associated metabolic abnormalities in patients who have
been unsuccessful with dietary, behavioral, and medical
interventions. Obesity-related diabetes is controlled by
bariatric surgery [145], especially gastric bypass [139] and
malabsorptive surgery [140]. However, its use as an
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intervention for type 2 diabetes is not yet recognized in
patients with a BMI below 35 kg/m2.
The mechanisms by which bariatric surgery achieve
improvement of diabetes are not well understood. It is
suggested that caloric restriction, weight loss, intestinal
malabsorption, hormonal changes in the entero insular axis
[141, 145], and rearrangement of the gastrointestinal
anatomy are possible features of such mechanisms.
Rubino et al. [142, 146] advocated that the presence of an
intestinal feature derived from excessive stimulus of the
upper digestive tract would cause deficient incretin action
and demonstrated in rats that bypassing a short segment of
proximal intestine directly ameliorates type 2 diabetes,
independently of effects on food intake, body weight or
malabsorption, i.e., the foregut theory. Strader et al. [143],
also in a rat model, suggested that lower intestinal
stimulation, the hindgut theory, increased synthesis and
release of peptide YY and GLP-1 through ileal interposition.
Whether bariatric operations exert an intrinsic antidia-
betes action beyond weight loss remains unproven. The
best of available evidence indicates that malabsorptive
operations presently offer the highest chances of revealing
weight independent mechanisms of diabetes resolution, but
smart manipulations of the food passage may open entirely
new avenues. Laparoscopic interposition of a segment of
ileum into the proximal duodenum associated to a sleeve
gastrectomy has been recently described as an effective
operation in controlling type 2 diabetes in a nonobese
population. Associated diseases and related complications
were also improved [144].
Blood sugar levels return to normal in 55–95% of
people with diabetes depending on the procedure
performed. However, the surgery is expensive and there
are risks involved, including a slight risk of death.
Additionally, drastic lifestyle changes are required and
long-term complications may include nutritional defi-
ciencies and osteoporosis [145].
III. Experimental drugs in development
for the treatment of diabetes
Many new drugs have entered the market in the past
10 years, and it is controversial that these new drugs are
superior to more established therapies [147, 148] probably
because many of these drugs are active on the same
Table 3 Some experimental drugs in development for the treatment of diabetes
Company Drug/Phase Description: Mechanism of action (MoA) Advantages Disadvantages
AMLN Byetta /Phase 3 New once-weekly formulation
of GLP-1 receptor agonist
Twice-daily version FDA approved; better






XOMA XOMA-52 /Phase 2 IL-1β antibody Excellent pharmacokinetics; improved
β-cell function; monthly injection
Costly, may be difficult to
administer (iv)
HALO PH20 /Phase 2 Recombinant hyaluronidase
enzyme
Clinically experienced compound; improves
glucose metabolism profile; potential to
reduce hypoglycemia; improves profile
of exogenous glucose
More “sticks” by patient
VVUS Qnexa /Phase 3 Combination therapy of
phentermine and topiramate
Synergistic combination product treats an
underlying factor of T2D, appetite
suppressant
Does not directly control
abnormal glucose profile
ARNA Lorcaserin /Phase 3 Serotonin 2C receptor agonist in
hypothalamus
Novel mechanism of action for appetite
control; Phase 3 data showed significant
weight loss




siRNA for SGLT2 Novel MoA and molecular target; data
demonstrates reduced expression of SGLT2
and improved glucose levels in rodents;
experienced in antisense technology
Drug delivery and
pharmacokinetics; limited
clinical data on the
new MoA





11 β-HSD1 is an enzyme that
converts inactive cortisone
into the potent biologically
active hormone cortisol
Once-daily doses of significantly
improved glycemic control, insulin
sensitivity and total-cholesterol levels.
Some adverse events
occurred in a mild or
moderate intensity;
limited clinical data
MoA mechanism of action, GLP-1 glucagon-like peptide 1; FDA U.S. Food and Drug Administration; IL 1 β interleukin-1 β; T2D type 2 diabetes; SGLT2
sodium-dependent glucose cotransporter 2; ZFP zinc finger protein transcription factor; VEGF vascular endothelial growth factor; 11β-HSD1 11 β-
hydroxysteroid dehydrogenase type 1
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molecular sights as previously approved drugs. Importantly,
as the number of patients with diabetes increases, develop-
ing new medicines that reduce the cost of long-term
treatment for this chronic disease will become a necessity.
The preclinical and clinical data recently presented at the
ADA and EASD meetings gives a preview of the new
drugs and technologies to come. Many of these drugs are
several years away from commercialization. However,
because of the new technology, new target or new delivery
method, the outlook remains positive for these drugs and
companies in the expanding market of diabetes control.
PPAR and GLP-1 receptor agonists
New technology and approaches for treating type 2 diabetic
patients is changing and the competition to secure the
growing market is enormous (see Table 3 for a summary).
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.
(AMLN), makers of Byetta, recently announced a new
formulation of this drug that changes the dosing from twice
daily to weekly.
Injectable peptide agonists of the GLP-1 receptor have
shown significant promise as anti-diabetic agents due to their
ability to amplify glucose-dependent insulin release and
preserve pancreatic β-cell mass. BYETTA is the first FDA-
approved agent in a class of diabetes therapies called incretin
mimetics [135]. Lixisenatide, under development by sanofi-
aventis, is a novel human GLP-1 receptor agonist for the
treatment of type 2 diabetes mellitus. In two phase 2 clinical
trials, lixisenatide improved glucose tolerance, resulted in
weight loss and lowered HbA1C, thereby causing signifi-
cantly more patients to achieve target HbA1C levels
compared with the placebo. Lixisenatide exhibited well-
established GLP-1-related gastrointestinal side effects, with
mild nausea occurring most frequently; a low frequency of
hypoglycemia was also reported. The results of phase 3 trials
are awaited for confirmation of the anticipated effects of
lixisenatide on glycemic measures and weight [203].
The new GLP-1 analog (VRS-859), created by Versartis,
is a recombinant fusion protein. That is, it is made up of
exenatide attached to XTEN. XTEN is a tail of an
hydrophilic amino acid sequence that covers exenatide,
hiding it from DPP-4 and good work for a longer time,
permitting less frequent dosing and fewer side effects. A
clinical study of VRS-859 in patients with type 2 diabetes is
planned for the first half of 2010.
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors, which belong to the
nuclear receptor superfamily and which regulate adipo-
genesis, lipid metabolism, insulin sensitivity, inflammatory
processes and blood pressure [149]. Fibrates, long used as
triglyceride-lowering agents, are now known to function as
activators of PPARα, while the already available thiazoli-
dinediones, rosiglitazone and pioglitazone act via PPARγ
to influence free fatty acid flux and reduce insulin
resistance and blood glucose levels. Future innovations
are expected whereby newer agents will combine PPARα,
PPARγ and possibly other PPAR-mediated properties.
Roche recently announced the beginning of a phase 3
clinical investigations for aleglitazar, its innovative PPAR
co-agonist R1439 that is uniquely designed to reduce
cardiovascular morbidity and mortality in high-risk patients
with type 2 diabetes. This decision is supported by data
from the Phase II SYNCHRONY study [151]. Aleglitazar
is a rationally designed molecule providing balanced dual
PPAR α/γ activation. Specifically it combines the improve-
ments in peripheral insulin sensitivity (and therefore
glycemic control) associated with PPAR γ activation, with
improved management of dyslipidemia, which is commonly
associated with PPAR α activation.
GPR119 agonists
G protein-coupled receptor 119 (GPR119) is expressed in
insulin-producing β-cells of pancreatic islets together with
L-cells of the gastrointestinal tract, and is involved in
insulin and incretin hormone release.
Arena Pharmaceuticals has recently reported that stimu-
lation of GPR119 under hyperglycemic conditions leads to
a dual nutrient dependent insulinotropic and incretinotropic
effect to maintain glucose homeostasis [152–154]. Unlike
receptors for GLP-1 and other peptides that mediate
enhanced glucose-dependent insulin release, GPR119 has
proven amenable to the development of potent, orally
active, small-molecule agonists [158].
Specific orally active GPR119 agonists may offer
significant promise as novel type 2 anti-diabetics acting in
a glucose-dependent fashion. The first GPR119 agonist
clinical candidates into Phase I trials (Arena/Ortho McNeil
APD597; Metabolex MBX-2982; Prosidion/OSI PSN821)
are promising and proof of concept with respect to
glycemic control and incretin release [158, 159].
Interleukin-1 β inhibitors
More recently, a new understanding of type 2 diabetes as a
disease caused by inflammation as been explored as a
source for new therapies [155, 156]. In type 2 diabetic
patients, high glucose concentrations induce the production
of interleukin-1 (IL-1) β in β-cells, leading to impaired
insulin secretion, decreased β-cell proliferation, and in-
creased apoptosis. Whereas most type 2 diabetes medicines
focus on maximizing insulin production by the pancreas or
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increasing the body’s sensitivity to insulin, IL-1 blockers
target the inflammatory response that can devastate insulin-
producing cells.
It has recently been reported that administration of anakinra
(Kineret, a recombinant IL-1-receptor antagonist and a
competitive inhibitor of IL-1 binding to type I IL-1 receptors)
for 13 weeks to type 2 diabetic patients decreased HbA1c by
0.46%, increased C-peptide secretion, and decreased the
proinsulin/insulin ratio and IL-6 levels, without an effect on
body weight or hypoglycemia [155]. Blockade of the master
pro-inflammatory signaling protein, IL-1, resulted in disease
improvement for type 2 diabetes patients [156].
XOMA-52, is a clinical stage IL-1β antibody for
patients with type-2 diabetes. XOMA-52 is unique to other
IL-1 β inhibitors because of its high affinity and long half-
life (22 days). As a result, patients need to be injected with
XOMA-52 once monthly and should increase patient
compliance. In addition to safety and pharmacokinetic data,
the Phase I trial demonstrated decreased HbA1c levels and
improved β-cell function. XOMA-52 is an attractive drug
candidate because it preserves endogenous insulin produc-
tion in patients with advancing type 2 diabetes. In addition
to clinical data, XOMA also presented detail mechanistic
rodent and in vitro data on XOMA-52, confirming the
results seen in the clinical study [157].
Halozyme
Co-administration of recombinant human hyaluronidase
accelerated the pharmacokinetics and glucodynamics of
insulin formulations [160]. For patients with type 1
diabetes, Halozyme (HALO) recently presented Phase 2
data that showed improved pharmacokinetics and glucody-
namics with patients receiving Lilly’s Humalog and co-
administration of Halozyme’s PH20 enzyme. PH20 is a
recombinant hyaluronidase enzyme that catalyzes the
hydrolysis of hyaluronic acid, a major constituent of the
interstitial barrier, and increases tissue permeability. This
study demonstrated an improved blood glucose metabolism
profile in patients taking the combination therapy, reflecting
a more physiologic glucose profile thereby likely reducing
the amount of exogenous insulin needed along with some
potential complications such as hypoglycemia [160, 161].
Appetite control
Anti-obesity drugs facilitate weight loss and contribute to
further amelioration of obesity-related health risks such as
type 2 diabetes. Several pharmaceutical companies are
interested in developing new targets and technologies [162].
VIVUS, Inc. (VVUS) recently presented data from a year-
long Phase 2 trial with Qnexa demonstrating reduced HbA1c
levels and helped patients achieve and maintain significant
weight loss through appetite suppression. Qnexa is a
combination therapy, of low dose phentermine and topiramate,
which in combination have synergistic effects through unique
molecular targets resulting in reduced appetite and increased
satiety—the two main mechanisms that impact eating behav-
iour. Qnexa, an investigational drug, is being developed to
address weight loss. In phase 2 and 3 clinical data to date,
Qnexa has demonstrated significant weight loss, glycemic
control, and improvement in cardiovascular risk factors.
Arena Pharmaceuticals, Inc. (ARNA) recently described
Phase 3 data from its BLOOM (Behavioral modification
and Lorcaserin for Overweight and Obesity Management),
demonstrating significant weight loss and reduced second-
ary endpoints associated with cardiovascular disease after
1 year of treatment compared to the placebo. Lorcaserin is a
novel serotonin 2C receptor agonist; selective activation of
this Gq-coupled GPCR in the hypothalamus leads to
appetite control and increased metabolism [163].
Sodium-dependent glucose cotransporter-2 inhibitors
The sodium-dependent glucose cotransporter (SGLT) is a
molecular target to directly enhance glucose excretion and
to safely normalize plasma glucose in the treatment of type
2 diabetes. There are two types of cotransporters: SGLT-1
and SGLT-2. Inhibitors of SGLT-2 block the reabsorption of
glucose (in the proximal tubule) from the renal filtrate,
whereas the SGLT-1 inhibitors suppress absorption of
glucose from the gut; these inhibitors help limit the amount
of glucose that is reabsorbed and retained in the body [164–
166]. The SGLT inhibitors do not interfere with glucose
metabolism, and thus, they are being used complementarily
to mainstream approaches to glucose regulation, such as
with the PPAR-γ agonists, DPP-4 antagonists, and GLP-1
analogues. The majority of inhibitors being developed as
antidiabetic agents are selective for SGLT- 2, but there are
some inhibitors of SGLT-1 and a mixed type of inhibitors.
Most of the SGLT-2 inhibitors, such as dapagliflozin
(BMS-512148), remogliflozin, sergliflozin, AVE2268,
189075, 869682, and T-1095, are derived from the
prototype phlorizin and structurally are glycosides. The
SGLT-2 inhibitors are also promising for other therapeutic
uses such as in obesity because they cause net loss of
calories from the body. The SGLT-2 inhibitors have a low
potential for hypoglycemia [166].
Dapagliflozin represents the first selective SGLT2 inhibitor
that functions by regulating renal glucose reabsorption.
Clinical trial data are limited, but available evidence supports
clinically significant reductions in fasting plasma glucose,
postprandial plasma glucose, hemoglobin A1c, and body
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weight with this agent [164]. In addition, dapagliflozin has
demonstrated excellent tolerability with safety data demon-
strated in both Phase 1 and Phase 2 studies. Results of
ongoing phase 3 clinical trials are necessary to demonstrate
efficacy and safety of this agent across various patient
populations and clinical scenarios [167]. Competitive
inhibition of SGLT2 therefore represents an innovative
therapeutic strategy for the treatment of hyperglycemia and/
or obesity in patients with type 1 or type 2 diabetes by
enhancing glucose and energy loss through the urine [166].
Isis Pharmaceuticals, Inc. (ISIS) recently presented
preclinical data on ISIS-SGLT2Rx [168], an antisense drug
that inhibits the production of SGLT2 that resulted in a
significant reduction in blood glucose levels in multiple
animal species as well as amelioration of diabetic compli-
cations such as cataract formation. ISIS-SGLT2Rx is the
first kidney-targeted antisense drug for type 2 diabetes and
Phase 1 study has been initiated. Isis is experienced in RNA
targeting drugs and has already commercialized the world’s
first antisense drug. This novel technology allows Isis to
target dysfunctional proteins through decreased transcrip-
tional levels thus modifying signaling pathways not
attainable through small molecule inhibition. Antisense
technologies may play a key role in finding drugs with
unique targets previously unreachable ultimately leading to
improved disease management and quality of life.
Regulation of endogenous gene expression using small
molecule-controlled engineered zinc-finger protein
transcription factors
Peripheral neuropathy is a common, irreversible complica-
tion of diabetes. Currently, the question being addressed is
whether or not gene transfer of an engineered zinc finger
protein transcription factor (ZFP) designed to upregulate
expression of the endogenous VEGF-A gene can protect
against experimental diabetic neuropathy (DN) [169–171].
VEGF has protective and regenerative effects on neuronal
cells in culture and in animal studies. No regenerative
therapies are currently available. Data from an earlier Phase
1, placebo-controlled study using VEGF Zinc Finger
Protein Activator (SB-509) in patients with diabetic
peripheral neuropathy showed statistically significant
improvements in neurological examination and quantitative
sensory testing as well as clinically relevant changes in
nerve conduction velocity [170].
Thus, Sangamo BioSciences, Inc. (SGMO) recently
described the results of phase 2 trials for SB-509 as a
treatment for DN resulting in statistically significant and
clinically relevant improvements in subjects [171]. DN is a
severe physiological consequence of chronic elevated blood
glucose levels and is seen in many patients with advanced
diabetes. SB-509 is an injectable plasmid encoding a DNA-
ZFP transcription factor designed to upregulate the endog-
enous expression of the gene encoding VEGF, a peptide
responsible for angiogenesis.
11 β-hydroxysteroid dehydrogenase type 1 inhibitor
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an
enzyme that converts inactive cortisone into the potent
biologically active hormone cortisol. This conversion occurs
within cells of key metabolic tissues including liver, adipose,
muscle and pancreas. Chronically elevated glucocorticoid
levels cause obesity, diabetes, heart disease, mood disorders,
and memory impairments. Excess 11 β-HSD1 or cortisol
leads to insulin resistance and metabolic syndrome in
animal models and in humans. Inhibiting 11 β-HSD1
activity signifies a promising therapeutic strategy in the
treatment of type 2 diabetes, insulin resistance, obesity,
lipid disorders, metabolic syndrome, and other diseases and
conditions that are mediated by excessive glucocorticoid
action [172]. Cortisol elevates blood glucose levels by
driving glucose production in the liver, and inhibiting the
uptake and disposal of glucose in muscle and adipose. Thus,
cortisol acts as an antagonist of insulin action, and 11 β-
HSD1 mediated production of cortisol has been hypothesized
to contribute to human insulin resistance, type 2 diabetes,
and the often-associated cardiovascular comorbidities.
Results from this double-blind, placebo-controlled Phase
IIb trial involving over 300 patients with type 2 diabetes
showed that treatment with once-daily doses of INCB13739
significantly improved glycemic control, as measured by
HbA1c, insulin sensitivity and total-cholesterol levels in
patients with type 2 diabetes [173].
Selectively inhibiting 11 β-HSD1 in humans might
become a new and promising approach for lowering blood
glucose concentrations and have a favorable effect on
insulin resistance, dyslipidemia, and obesity in type 2
diabetes. A large variety of 11 β-HSD1 inhibitor classes
have been synthesized [174–176], and some are under
investigation by the pharmaceutical industry to treat type 2
diabetes and obesity [177]. The modulation of 11 β-HSD
type 1 activity with selective inhibitors has beneficial
effects on various conditions including insulin resistance,
dyslipidemia, and obesity. A number of 11 β-HSD1
inhibitors (carbenoxolone, AZD4017, BVT116429, PF-
00915275, PF-915275, PF-877423) are being investigated
by many major pharmaceutical companies for treatment of
type 2 diabetes and other abnormalities associated with the
metabolic syndrome. BVT.2733 reduced food intake but
prevented a concomitant reduction in lean body mass and
energy expenditure. The latter effects may have contributed
to improved glucose tolerance. These compounds improve
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insulin sensitivity in the liver and adipose tissue and
possibly may cause weight reduction, as shown in animal
studies. They have low potential for hypoglycemia.
FGF-21 for the treatment of type 2 diabetes
Fibroblast growth factor 21 (FGF-21) is a recently discovered
metabolic regulator. FGF-21 activity depends on β-klotho, a
single-pass transmembrane protein. β-klotho physically inter-
acts with FGF receptors 1c and 4. FGF-21 is produced
predominatly by the liver that exerts the unique role in the
regulation of carbohydrate and lipid metabolism in the liver,
adipose tissue and pancreas [178]. FGF-21 stimulates glucose
uptake in adipocytes, reduces glucagon secretion and lowers
blood glucose and triglyceride levels when administrated to
diabetic rodents and monkeys. Its administration in diabetic
primates led to a sustainable improvement in glucose control
without occurrence of hypoglycemia, a significant improve-
ment of diabetic dyslipidemia and a mild weight loss
without any significant side effects [179]. FGF-21 also
preserves pancreatic insulin content and β-cell mass when
administered to diabetic mice. Finally, FGF-21 protects
animals from diet-induced obesity when overexpressed in
transgenic mice [178]. These data indicate that FGF-21
might offer a promising new therapeutic approach to treat
type 2 diabetes. All of these characteristics make FGF-21 a
hot candidate for the treatment of patients with obesity and
type 2 diabetes mellitus.
Antidiabetic effects of glucokinase activators
Glucokinase (GK) plays a key role in glucose homeostasis
by controlling the rate of glucose metabolism in many
tissues. GK is believed to function as the primary glucose
sensor in a range of neuro/endocrine sentinel cells (includ-
ing β-cells) that are involved in glucose homeostasis. In
pancreatic β-cells, GK acts as a sensor for glucose
stimulated insulin release and in hepatocytes it catalyzes
the first step of glucose metabolism. The relationship
between changes in GK activity and fasting plasma glucose
in humans with GK diseases has been well established for
both loss and gain of function mutations.
Such strong biological rationale for targeting GK as a
potential anti diabetic therapy led to the discovery of small
molecule allosteric GK activators (GKAs). GKAs bind to an
allosteric site 2 nm away from the bound glucose site and act
as non-essential mixed-type enzyme activators [180].
Evidence suggests that the glucose lowering effects in
rodents are mediated by dual effects on increasing plasma
insulin levels and suppression of hepatic glucose levels as
assessed by a pancreatic clamp [181]. Early data in humans
recently presented suggests that GKAs offer a promising
new therapeutic approach to treat type 2 diabetes [182].
PSN010 is an oral glucokinase activator, being developed
for the treatment of type 2 diabetes. By activating the enzyme
glucokinase, PSN010 is anticipated to lower blood glucose
levels by increasing uptake of glucose in the liver and
increasing insulin secretion from the pancreas. PSN010 was
discovered and developed in-house through OSI’s diabetes
and obesity research efforts. The project arising from a
research collaboration with the Vanderbilt University Diabetes
Center and Tanabe Seiyaku Co. Ltd. PSN010 is currently in
Phase I clinical trials. In January 2007, OSI entered into a
licensing agreement granting Eli Lilly exclusive rights to its
GKA program, which includes PSN010.
Gluconeogenesis inhibitors
Fasting hyperglycemia in diabetes is well correlated with
accelerated hepatic glucose production in type 2 diabetes
patients; free fatty acids also induce gluconeogenesis [183]. In
animal studies, it has been shown that glucose production in
the liver can be inhibited both by substances that act directly
on gluconeogenesis and by substances that inhibit fatty-acid
oxidation. Therefore, inhibition of both free fatty acid release
(such as by SDZ WAG 994) and fatty-acid oxidation (such
as by β-aminobetaine [emeriamine]) in the liver may be
efficient modalities of treatment to prevent fasting hypergly-
cemia in diabetics [182]. Benfluorex, a derivative of
fenfluramine, lowers plasma glucose by inhibition of
gluconeogenesis [182]. Inhibition of fructose 1, six bisphos-
phatase, the key hepatic enzyme in gluconeogenesis is also a
therapeutic target for treatment of type 2 diabetes [184]. A
potent and specific inhibitor of this enzyme [MB06322 (CS-
017)] may be useful in type 2 diabetes [185].
Oral insulin
The prospect of a non-injectable means of insulin delivery
has always been very attractive. The potential market for an
oral form of insulin is assumed to be enormous, thus many
laboratories have attempted to devise ways of moving
enough intact insulin from the gut to the portal vein to have
a measurable effect on blood sugar.
Many biopharmaceutical companies (Apollo Life Sciences,
Bicon, Biodel Inc, Oramed Pharmaceuticals Inc) are currently
developing their oral insulin products.
Biodel, Inc. is developing an oral formulation of insulin
(VIAtab) designed to be administered sublingually. In a
Phase I study, VIAtab delivered insulin to the blood stream
quickly and resembled the first-phase insulin release spike
found in healthy individuals. The company claims that an
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oral insulin therapy would be more convenient than
currently available injectable or inhalable therapies, and
they expect that convenience to result in increased insulin
usage among the currently underserved early-stage patients
with type 2 diabetes, thus helping to create better long-term
outcomes for that patient population.
Oramed Pharmaceuticals, Inc. is currently conducting
Phase 2b clinical trials of its oral insulin capsule, ORMD-
0801 on 30 patients diagnosed with type 2 diabetes [186].
Oramed’s platform technology has two components: 1) A
chemical make-up that protects insulin during passage
through the gastrointestinal tract, and 2) Absorption
enhancers so that insulin could be absorbed by the intestine.
Oramed Pharmaceuticals, Inc. in phase 1 clinical trials, has
demonstrated that its oral insulin is safe, well tolerated, and
has consistently reduced glucose and c-peptide levels in
patients [187].
An alkylated, PEGylated, amphiphilic insulin conjugate
(HIM-2, Biocon Corp., India) increased oral formulation of
insulin in dogs and has reached Phase 2 clinical studies [188].
One of the major challenges in biopharmaceutical develop-
ment, therefore, continues to be the need for effective oral
delivery systems and a number of different approaches have
already been used to promote oral delivery of insulin [204].
Insulin mimetics
The concept of developing insulin mimetics is a long
established one, but recent years have seen important
developments. For example, protein tyrosine phosphatases
(PTPs) are enzymes that control signal transduction path-
ways, and inhibition of individual PTPs can result in
activation of therapeutically relevant kinase cascades.
Tyrosine phosphatase 1B (PTP1B) is implicated as a
negative regulator of insulin receptor signaling, so small-
molecule inhibitors of this enzyme are being investigated as
potential insulin mimetics or insulin augmenting agents.
Inhibition of PTP1B in muscle and liver, down-regulates
insulin signaling, thereby improving insulin sensitivity
[189]. These compounds have a low potential for hypo-
glycemia. A number of compounds synthesized [190] as
well as isolated from various plants have been found to be
potent inhibitors of protein tyrosine phosphatase 1B.
During the last decades, a large body of evidence has
accumulated to suggest that organo-vanadium compounds
exert various insulin-like effects in both in vitro and in vivo
systems. These include their ability to improve glucose
homeostasis and insulin resistance in animal models of type
1 and type 2 diabetes mellitus. In addition to animal studies,
several reports have documented improvements in liver and
muscle insulin sensitivity in a limited number of patients
with type 2 diabetes [191, 192]. Among these compounds,
vanadium (IV) oxo bis(maltolato) was the first to be
investigated for its higher potency over inorganic vanadium
salts in eliciting insulin-like properties in both in vitro and
in vivo systems [193]. There are some concerns about the
potential toxicity of available inorganic vanadium salts at
higher doses and during long-term therapy. Therefore, new
organo-vanadium compounds with higher potency and less
toxicity need to be evaluated for their efficacy as potential
treatment of human diabetes.
IV. Gene-based therapies for the treatment of diabetes
An emerging, promising alternative to the traditional
treatments of diabetes (injections of insulin and islet
transplantation) is the gene-based therapy. Gene therapy,
developing rapidly as a result of advanced biotechnologies
and the finalized Human Genome Project, is frequently
highlighted as one of the most promising technologies of
the 21st century. Although some obstacles remain to be
overcome, the risk-benefit balance of gene therapy in
diabetes seems to be superior when compared to all other
currently used treatment systems.
The transfer of genetic material with therapeutic interest
is the aim of gene therapy. This process requires three basic
elements: (a) understanding of the pathogenesis of a
disease, (b) the targeted genetic sequence, and (c) stable
delivery systems providing the targeted tissues with the
level and duration of the gene expression necessary to
produce the desirable therapeutic effect [205]. Diabetes is
an ideal target for gene therapy application, since it
provides targets that include suppression of autoimmunity,
restoration of insulin responsiveness, functional replace-
ment of pancreatic islets and correction of vascular and
nerve damage associated with prolonged hyperglycemia.
The cloning of the insulin gene, in the late 1970s, opened
up doors for this innovative therapy. In fact, hepatocytes,
myocytes, pituitary and exocrine cells have been trans-
formed into insulin-producing substitutive cells [206].
However, even this potent therapeutic approach faces
several limitations. Pro-insulin needs to be converted into
insulin by specific enzymes termed convertases, which are
not expressed in the majority of substitutive cells. Although
this can be improved with the aid of alternative enzymes,
none of these cells respond to insulin secretagogues by a
physiological secretion of insulin. These observations
question the capability of gene-therapy constructed non-
pancreatic tissues to keep a stringent control over blood
glucose concentration as it is provided by functional β-
cells. A more promising approach has been to express
pancreatic endocrine developmental factors, such as pan-
creatic duodenal homeobox-1 (PDX-1), NeuroD and
neurogenin-3/betacellulin (Ngn3/Btc), promoting differen-
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tiation of non-endocrine cells in order to reach a β-cell or
islet phenotype, enabling synthesis and secretion of insulin
in a glucose-regulated manner [207]. For example, systemic
deliver of PDX-1 to the livers of streptozotocin (STZ)-
treated mice, using a first generation adenovirus gene
therapy vector, was shown to induce activation of endog-
enous pro-insulin 2 gene, leading to increased levels of
serum insulin and decreased levels of blood glucose.
Notably, despite the transience of the adenoviral constructs,
insulin secretion occurred for a period of 4–6 months [54].
An ex vivo approach for transduction of PDX-1 in adult
human hepatocytes, have also shown increased expression
and secretion of insulin in a glucose-regulated manner, as
well as increased expression of somatostatin, glucagon,
glucokinase, glucose-transporter 2 (GLUT 2) and several
endocrine developmental factors. When transplanted under
the renal capsule of diabetic mice, hyperglycemia was
ameliorated for prolonged periods of time [209]. Another
recent study in a mouse model of diabetic pancreatic
damage involving injection of mice with STZ, have shown
that transplantation of pancreas with Pdx1-transduced
ASCs (adipose tissue-derived stem cells) significantly
decreases blood glucose levels and increases cell survival.
Moreover, Pdx1-ASCs were shown to be stably engrafted
in the pancreas, to acquire a functional β-cell phenotype
and partially restore pancreatic function in vivo [210]. The
use of helper-dependent adenoviral (HDAd) system to
deliver a combination of NeuroD and Btc genes was also
shown to be a promising therapeutic strategy. Indeed,
increased expression of these factors lead to marked
improvement in fasting hyperglycemia in STZ-treated
diabetic mice, restore of the glucose tolerance, as well as,
of the serum insulin levels for 3 months [211]. Another
good example of a promising therapeutic option is the use
of viral vectors carrying Ngn3 and Btc to improve glucose
and lipid metabolic abnormalities associated with insulin
deficiency. Indeed, experimental studies using STZ-diabetic
mice have shown that Ngn3/Btc gene delivery by adeno-
viral vectors to pancreatic islets restores glucose-stimulated
insulin secretion and reverses hyperglycemia in these
animals. The treatment also normalizes hepatic glucose
secretion and reverses ketonemia. Moreover, this approach
was able to restore hepatic glycogen content and hepatic
lipogenesis-related gene transcripts back to nondiabetic
levels. This study also shows that the neo-islets display
electron-dense granules that are similar in appearance to
those in pancreatic islets and exhibit a very similar
transcription profile on microarray-based transcriptome
analysis as compared to pancreatic islets [212].
Improvement of quality life and health condition of
diabetic patients may also pass by the direct treatment of
diabetic complications, such as neuropathy, renal damage,
retinopathy, impaired wound healing and cardiovascular
disease. One of the best examples for a possible gene therapy
approach is proliferative diabetic retinopathy. This pathology
is the leading cause of blindness worldwide and is character-
ized by retinal neovascularization and increased vascular
permeability [213–215]. The eye constitutes a privileged
organ to assess the effectiveness of anti-angiogenic therapies,
since it is non-invasively available for imaging techniques
that allow the study of progression of neovascularization.
Vascular endothelial growth factor (VEGF) is considered a
central player in the regulation of the pro-angiogenic process,
and, therefore, has been proposed as the therapeutic target for
treatment of diabetic retinopathy and other chronic diabetic
complications related to neovascularization. However, cur-
rently used therapeutic approaches targeting VEGF in
diabetic retinopathy carry several drawbacks. Some of the
approaches developed and clinically tested to reduce neo-
vascularization in diabetic retinopathy include intravitreal
injections of antibodies that bind to and block VEGF action
and its receptors. Some of these antibodies, such as
Ranibizumab (Lucentis) and Bevacizumab (Avastin), were
recently approved by the FDA and are commercially
available. However, intravitreal administration is associated
with increased intraocular hypertension and inflammation,
whereas intravenous injection was observed to have signif-
icant risks of thromboembolic events. Another disadvantage
of these therapeutic approaches is the requirement of
frequent and costly injections. Therefore, alternative thera-
pies that silence VEGF levels—by interference RNA
(iRNA), for example—are considered as a new generation
of more effective strategies [205, 216].
Another good example for the promising use of gene
therapy is diabetic critical limb ischemia (CLI). CLI is one of
the leading causes of disability among diabetic patients and is
the most common cause of non-traumatic amputation in
diabetes. It is a disease manifested by diminished blood flow
to the legs and appears to be associated, at least in part, with
loss of cell and tissue response to ischemia, leading to
impairment of the wound healing and angiogenic responses.
A recent study using a diabetic model of critical limb ischemia
have shown that intramuscular injection of an adenovirus
encoding a constitutively active form of HIF-1α (the key
regulator of cell response to low oxygen) into the ischemic
limb of diabetic mice increases the recovery of limb perfusion
and function, reduces tissue necrosis, rescues the diabetes-
associated impairment of circulating angiogenic cells, enhan-
ces endothelial nitric oxide synthase activation, and increases
vessel density and luminal area in the ischemic limb [217].
Another recent study also shows that local sustained release
of VEGF, using adenovirus vector-mediated gene transfer,
accelerates experimental diabetic wound healing, by stimu-
lating angiogenesis, epithelialization and collagen deposition.
Administration of adenoviral VEGF together with
angiopoeitin-1 (Ang-1) has also been shown to be an
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effective and a promising therapeutic approach in the
treatment of diabetic myocardial injury after an acute
hypoxic challenge, such as a heart attack. Preclinical data
demonstrates the efficacy of co-administration of adenovi-
ral VEGF and Ang-1 in increasing angiogenesis, increas-
ing heart collateral development and reducing ventricular
remodeling in the infarcted diabetic myocardium [218].
Since obesity is associated with an increased risk of
developing insulin resistance and type 2 diabetes, there has
been great interest in the development of gene therapies for the
control of obesity. Leptin gene therapy is one of the most
exciting and promising approaches in this field. This has been
achieved by two different systems based on the transfer of the
leptin gene to muscles using viral vectors or enhanced
electroporation (EP) [219]. Intracerebroventricular injection
of recombinant adeno-associated virus encoding leptin in rats
consuming a high-fat diet (HFD) have shown that leptin
treatment reduces intake and blocks the HFD-induced
increase in weight, adiposity and metabolic variables. Blood
glucose was shown to be slightly reduced but within the
normal range. Treatment with leptin significantly augmented
uncoupling protein-1 (UCP1) mRNA expression in brown
adipose tissue, indicating increased thermogenic energy
expenditure [220]. Through muscle EP, the levels of serum
leptin increased by about 200 fold in leptin-treated mice over
control mice. Moreover, electrogene transfer resulted in
hyperleptinemia, decreased food intake and lower body
weight. The production of insulin also decreased, but the
blood glucose levels remained normal [221].
Despite all the promising results, there are still several
obstacles to overcome. One of them is the nature of the
gene delivery system. The ideal gene therapy vector would
allow an adequate expression of the transgene for the
necessary period of time, it would have the ability to target
the disease site and deliver the genetic material in a safe
manner. Unfortunately, the currently available gene vectors
do not meet all of these requirements. Whereas viral vectors
have been proven to be efficient in terms of cell targeting
and gene expression, the possibility of host immune
response and the random integration of the virus into the
host genome raises some doubts about the safety of these
vectors [222]. In fact, a widely reported clinical trial in
patients with SCID-X1 resulted in T-cell lymphoma after
the application of retrovirus gene therapy [223]. On the
other hand, nonviral vector systems are more likely to
satisfy biosafety concerns, but their transduction efficiency
and the lack of cell specificity are still downsides.
Conclusion
The prevalence of diabetes has been increasing worldwide
and is expected to continue to rise over the next 50 years
[2, 224]. The accompanying increase in the prevalence of
diabetes-related complications and the occurrence of diabe-
tes among younger adults, children, and adolescents is
likely to have a substantial impact on healthcare costs, with
cardiovascular disease and other chronic complications of
diabetes accounting for more than one quarter of all direct
expenses [3]. Patients with diabetes should be followed
closely to ensure that they achieve and maintain both
glycemic and nonglycemic treatment objectives. Given the
loss of 80% of β-cell function at diagnosis of diabetes, as
well as the 50% prevalence of pre-existing coronary heart
disease at diagnosis, a more aggressive approach from the
earliest stages of disease is clearly indicated [225]. A
number of new therapeutic agents have been introduced
[75], and a large number of new compounds are in various
stages of development for the treatment of type 2 diabetes
[208] and this reflects the enormous impact of diabetes on
public health. Prevention and major changes in lifestyle
factors such as diet and physical exercise will also be
needed to contain the growing burden of diabetes.
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